What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) fell 10.1% in the afternoon session after the company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast that fell short of analyst predictions.
While NeoGenomics' fourth-quarter revenue grew 11% to $190 million, beating Wall Street's estimates, investors appeared more concerned with the company's outlook. The guidance for full-year 2026 adjusted earnings per share and adjusted EBITDA both came in below analyst consensus. Adding to the concerns, the full-year 2025 results showed a 37% increase in net loss to $108 million, even as revenue grew. The weaker-than-expected forecast seemed to overshadow the strong quarterly performance, prompting a negative reaction from the market.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
NeoGenomics’s shares are extremely volatile and have had 39 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 10 months ago when the stock dropped 34.8% on the news that the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-year revenue guidance exceeded Wall Street's estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.
NeoGenomics is down 13% since the beginning of the year, and at $10.23 per share, it is trading 22.6% below its 52-week high of $13.22 from January 2026. Investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at an investment worth $180.08.
The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave, it’s free.
